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Background: FDG-PET–CT-based selective lymph node (LN) irradiation is standard using 3D-conformal
techniques for locally advanced NSCLC. With newer techniques (intensity-modulated/volumetric-arc
therapy (IMRT/VMAT)), the dose to non-involved adjacent LN decreases, which raises the question
whether FDG-PET–CT-delineation is still safe. We therefore evaluated the impact of adding linear
endosonography with needle aspiration (E(B)US-NA) to FDG-PET–CT in selective nodal irradiation.
Methods: Based on literature data on sensitivity and specificity of E(B)US-NA in FDG-PET–CT-staged
NSCLC, false negative (FN) rates for different constellations of CT, PET and E(B)US-NA were calculated.
The algorithm was tested on consecutive patients with N2/N3 disease referred for radiotherapy in
Leuven and Maastricht.
Results: An algorithm determining when to include LN in the GTV is proposed, based on data from 5
meta-analyses. Adding E(B)US-NA to FDG-PET–CT decreases the FN-rate, but for PET-positive and E(B)
US-negative LN, FN rates are still 14–16%. In Leuven 520 LN were analyzed, in Maastricht 364 LN; with
E(B)US-NA a geographical miss was avoided in 2 (2/40 = 5%) and 1 (1/28 = 4%) patients, respectively.
Conclusions: E(B)US-NA in addition to FDG-PET–CT for mediastinal staging decreases the risk of a geo-
graphical miss with 4–5%. The impact of this small decrease on survival is unknown. The proposed algo-
rithm may guide the radiation oncologist when to include LN in the nodal GTV.
 2016 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology xxx (2016) xxx–xxxLung cancer is the most common cancer worldwide [1]. The
prognosis of patients with locally advanced (LA) or stage III non-
small cell lung cancer (NSCLC) has improved over the last two dec-
ades. The 5 year overall survival is about 30% [2]. For patients in
good general condition, stage III NSCLC is treated with a combined
modality approach. The standard treatment for many of these
patients is chemoradiation [2]. It has been shown that it is safe
to omit irradiation of elective lymph nodes (LN) when using
FDG-PET–CT scan to determine the target LN [3,4]. However, this
has only been shown for three-dimensional conformal radiation
therapy (3D-CRT) techniques. The introduction of intensity-
modulated radiotherapy (IMRT) and volumetric arc therapy
(VMAT) allowed more shaped distributions and sharper dose gra-
dients than previously possible. In particular for lung cancerpatients where the tumor is in close proximity to an organ at risk,
or where the target volume includes a large volume of an organ at
risk, IMRT or VMAT may potentially be beneficial in minimizing
normal tissue toxicity and in adequately covering the target vol-
ume [5,6]. One of the major concerns however is the decrease in
incidental nodal irradiation with IMRT compared with 3D-CRT
[7]. With 3D-CRT, adjacent LN not included in the target volume
still receive a substantial radiation dose. There are indications that
the incidental low doses to regional uninvolved LN contribute to
the low regional recurrence rates [3,8]. Therefore, the question
arises whether selective nodal irradiation based on FDG-PET–CT
is still safe when using modern techniques such as IMRT or VMAT.
Linear endosonography (endobronchial ultrasound (EBUS) and/
or esophageal ultrasound (EUS)) with needle aspiration (E(B)US-
NA) is a technique that can give additional pathology-based infor-
mation on whether LN are malignant or not [9]. With a sensitivity
of >90% and specificity of 100% it has been shown to be an accurateo use E
2 Node irradiation in NSCLC: added value of E(B)US-NAtool in lung cancer staging in patients with enlarged LN on CT and/
or PET-positive LN [10,11]. We therefore evaluated the impact of
adding E(B)US-NA-mapping of the mediastinal LN to PET–CT on
avoidance of a geographical miss, and on the size of nodal gross
tumor volume (GTV) in patients treated with radiotherapy.
The aim of this study was first to make a practical algorithm for
daily clinical practice on when to include LN in the GTV in locally
advanced NSCLC. This algorithm was based on literature data that
included sensitivity and specificity data of E(B)US-NA in FDG-PET–
CT staged NSCLC. Second, we wanted to test this algorithm on a
patient group and analyze how E(B)US-NA mapping impacts on
the number of LN considered to be malignant, and on the nodal
GTV. First we used a patient group treated at the University Hospi-
tals of Leuven, and second an independent patient group treated at
MAASTRO clinic Maastricht.Methods and materials
Algorithm
We first retrieved the expected prevalence for different results
of CT (enlarged vs. normal-sized) and PET-scan (positive vs. nega-
tive) from literature. We analyzed mediastinal and hilar lymph
nodes (LN) together, as the sensitivity of E(B)US-NA to detect
malignancy in hilar LN is similar to its performance in mediastinal
LN [11]. Secondly, false negative (FN) rates of LN for different con-
stellations of PET, CT and E(B)US-NA based on these literature data
were calculated, to evaluate the safety of excluding LN based on CT,
PET and E(B)US-NA findings. FN rates were calculated since they
have the largest consequence on geographical miss.
Our aim was to propose a practical algorithm that can guide a
radiation-oncologist when to include LN in the nodal gross tumor
volume (GTV). This algorithm provides the risk of involvement of
a LN based on FDG-PET–CT scan and E(B)US-NA.Patients Leuven
Consecutive NSCLC-patients referred for radiotherapy (RT) with
curative intent in 2012 and 2013 with N2 or N3 disease on
FDG-PET–CT scan and who were subjected to E(B)US-NA were
included. All stage III NSCLC patients referred for RT have a
FDG-PET–CT scan and E(B)US-NA with full mapping of mediastinal
LN before RT-planning. Details of the FDG-PET–CT procedures can
be found in the Supplementary file. All patient data are entered in a
prospective database. This is a retrospective study on patients from
this database.
LN stations 1, 2R, 2L, 3 (=3A + 3P), 4R, 4L, 5, 6, 7, 8, 9, 10-11L, 10-
11R (=13 LN stations) were visually analyzed on CT- and PET-scan
[13]. On the CT-scan, LN were considered to be positive when the
short axis perpendicular to the longest diameter of the LN was
P10 mm. On the PET–CT scan, all LN were visually analyzed for
FDG-avidity, making use of the written report of the nuclear physi-
cian. No SUV-determination was performed because there is no
proven added value compared to visual assessment [14].
With E(B)US-NA all LN stations are inspected, and a needle aspi-
ration is done in enlarged or normal sized suspicious LN measuring
>5 mm, when technically feasible [15]. In each patient first the N3
nodes, thereafter the N2 nodes, and finally the N1 nodes are sam-
pled in order to avoid spurious upstaging of the patient through
contamination.Patients Maastricht (external validation)
An independent dataset was obtained from a prospective data-
base from Maastricht. Inclusion criteria were identical as in Leu-
ven: consecutive NSCLC patients with N2-N3 disease on PET–CTPlease cite this article in press as: Peeters ST et al. Selective mediastinal node irr
(B)US-NA information in addition to PET–CT for delineation?. Radiother Oncolscan, referred for RT, and who were subjected to an E(B)US-NA
for mediastinal mapping. LN stations 1–11 were analyzed on the
PET-scan. No information is available on the size of the LN. With
E(B)US-NA all LN stations are inspected, and a needle aspiration
is done in at least one PET-positive LN to prove N2 or N3 disease.
After that, suspicious or enlarged PET-negative LN are sampled,
as all PET-positive LN are included in the GTV anyway.Test of algorithm
We applied the algorithm on both patient populations. We ana-
lyzed the impact of using E(B)US-NA-mapping in addition to FDG-
PET–CT, first on the number of LN that were considered malignant,
and secondly on the number of LN to include in the nodal GTV.
Standard delineation of LN nowadays is based on FGD-PET–CT only
in 3D-conformal RT and consists of all FDG-PET positive LN [16].Results
The expected prevalences of malignant LN (pretest probability)
for different constellations of FDG-PET–CT were previously
described in a study from Hellwig et al., based on 5 meta-
analyses (Fig. 1, 4th column) [17]. When comparing enlarged LN
on CT to normal-sized LN, FDG-PET has a higher positive predictive
value (78% vs. 70%), but also a higher false negative (FN) rate (13%
vs. 6%).
Using these values, the cancer prevalence was calculated, taking
into account the false negative (FN) rate of E(B)US-NA of 20%
(Fig. 1, 6th column). This FN rate of 20% was described by Detter-
beck et al. and Micames et al. [12,18].
In FDG-PET-negative LN, the addition of E(B)US-NA decreases
the FN rate with 10% for enlarged LN (from 13% to 3%, relative
reduction of 77%), and with 5% for normal-sized LN (from 6% to
1%, relative reduction of 83%) (Fig. 1, 4th and 6th column). An algo-
rithm determining when to include a LN in the GTV is proposed
(Fig. 1, last column). Based on this algorithm it is safe to exclude
LN that are both PET-negative and E(B)US-negative, regardless of
the size of the LN on CT-scan. LN that are PET-negative but E(B)
US-positive should be included in the GTV as the risk of a false pos-
itive NA is negligible. For LN that are PET-positive but E(B)US-
negative, the risk of having a false negative result is still 14–16%,
and they are therefore included in the nodal GTV. This means that
compared to PET-based delineation only, the addition of E(B)US-
NA to PET–CT can increase the volume of the nodal GTV, but not
decrease (Fig. 1). Exceptions to this rule are situations where a
valid benign reason for PET-positivity is found at pathological
examination in case of symmetrical PET-positive LN.
Forty consecutive patients treated at the University Hospitals
Leuven were included. We determined the number of patients in
which addition of a full E(B)US-NA nodal station mapping before
RT resulted in a different nodal GTV using the algorithm. Patient
and tumor characteristics are shown in Table 1. Mean age at diag-
nosis was 64 years. Fifty-five percent of patients had a right-sided
primary tumor, 45% a left-sided. Four patients had a solitary
metastasis (two with brain, one with adrenal and one with a renal
metastasis) and were considered for treatment with radical intent.
For all patients, the 13 LN stations were visually inspected on
CT-scan en PET-scan. This resulted in a total of 520 analyzed LN
stations (Fig. 2). 114 LN were enlarged (P10 mm), of which 105
were PET-positive. Twenty normal-sized LN were PET-positive. A
total number of 82 LN stations were biopsied with E(B)US-NA,
corresponding to a mean of 2.1 LN stations per patient (standard
deviation (SD) 0.9; range 1–5). All samples were representative;
49 were malignant, and 30 benign (Fig. 2). In one patient EBUS
showed a non-representative sample in 4L, but with theadiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E
(2016), http://dx.doi.org/10.1016/j.radonc.2016.05.023
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Fig. 1. Expected prevalence of cancer for different constellations of CT, PET and E(B)US. The last column indicates if the LN should be included in the GTV: (1) E(B)US does not
change GTV compared to PET–CT only, (2): E(B)US sometimes changes GTV, (3): E(B)US always changes GTV (=increased volume). * based on Hellwig et al. [17]; y prevalence
of cancer taking into account a FN rate of E(B)US of 20% (15);  with exception of symmetrical FDG-PET positive LN with a non-malignant diagnosis (anthracosis, silicosis,
granulomatous disease. . .) after adequate full EBUS-mapping. Abbreviations: LN = lymph node; GTV = gross tumor volume; E(B)US = endobronchial/esophageal ultrasound.
Table 1
Patient and tumor characteristics for Leuven and Maastricht.
Characteristics Leuven
(n = 40)
Maastricht
(n = 28)
Age (years) Mean ± SD 64 ± 10 65 ± 10
(Range) (42–86) (48–81)
FEV1 (%) Mean ± SD 79 ± 21 80 ± 22
(Range) (40–122) (32–120)
(n = 37) (n = 27)
Gender Male 22 19
Female 18 9
Tumor
location
Right upper lobe 15 11
Right middle lobe 2 1
Right lower lobe 5 3
Left upper lobe 13 2
Left lower lobe 5 9
Unknown (=T0) 0 2
Histology Squamous cell
carcinoma
10 7
Adenocarcinoma 24 9
Large cell 5 11
Large cell
neuroendocrine
0 1
Unknown 1 0
T-stage T1 11 3
T2 13 11
T3 9 7
T4 7 5
T0 0 2
N*-stage N2 26 18
N3 14 10
M-stage M0 35 28
M1a 0 0
M1b 5 0
Stage IIIA 18 16
IIIB 17 12
IV 5 0
Abbreviations: SD = standard deviation; FEV1 = Forced Expiratory Volume in 1 s;
TNM 7th edition.
* N-stage based on FDG-PET–CT.
S.T. Peeters et al. / Radiotherapy and Oncology xxx (2016) xxx–xxx 3subsequent EUS a representative sample in this LN was obtained.
In 2 patients, E(B)US-NA detected a malignant LN not enlargedPlease cite this article in press as: Peeters ST et al. Selective mediastinal node irr
(B)US-NA information in addition to PET–CT for delineation?. Radiother Oncolon CT-scan and not FDG-avid on the PET-scan. Thus, a geographical
miss was avoided in 2 patients (5.0%; 95% confidence interval (CI):
0.0%-11.8%). The first patient was staged as N2 with FDG-PET, but
had a N3 LN in contralateral station 4. The second patient had a
normal-sized PET-negative LN in station 7 malignant with E(B)
US-NA. The time between PET–CT-scan and E(B)US-NA in these 2
patients was 8 and 5 days, respectively. None of the enlarged and
PET-negative LN that were biopsied with E(B)US-NA were malig-
nant in this population.
E(B)US-NA was negative in 15 PET-positive LN (11 enlarged and
4 normal-sized) from 9 patients. In 6 of these patients, the LN were
described as slight to moderately hypermetabolic whereas the pri-
mary tumor was intensely FDG-avid; in one these 6 patients dust
laden macrophages were found at pathology. In 3 patients signs
of lung inflammation or infection were seen on CT-scan and/or
PET-scan.
We determined the incidence of patients in which addition of E
(B)US-NA resulted in a different nodal GTV on an independent
external validation cohort of patients treated in Maastricht.
Twenty-eight patients with N2 or N3 disease and referred for RT
were included in this study. Patients and tumor characteristics
are shown in Table 1. Fig. 3 shows the results of using the algo-
rithm, without taking into account the LN size. A total number of
37 LN were investigated with E(B)US-NA, with a mean of 1.3 LN
per patient (SD 0.6; range 1–3). Five LN were not representative
at pathological examination. In this patient population, a geo-
graphical miss (PET negative and E(B)US-NA positive) was avoided
in one patient (3.6%; 95% CI: 0.0–10.4%) by adding E(B)US-NA to
the FDG-PET–CT scan. This patient had a N3 contralateral hilar
adenopathy diagnosed with E(B)US-NA.Discussion
In this study we propose a practical algorithm that defines
when to include LN in the GTV for radiotherapy delineation, based
on literature data on sensitivity and specificity of E(B)US-NA inadiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E
(2016), http://dx.doi.org/10.1016/j.radonc.2016.05.023
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Fig. 2. Overview of the number of analyzed LN with CT, PET and E(B)US-NA in 40 patients from Leuven. Abbreviations: LN = lymph node; n = number of LN; PET+: with
pathological FDG-uptake; PET: no pathological FDG-uptake; E(B)US-NA = endobronchial/esophageal ultrasound with needle aspiration; E(B)US+: malignant pathology; E(B)
US-: benign or normal LN at pathology.
EBUS-NA
LN with
EBUS-NA
(n=37*)
PET
Analyzed LN
staons       
n=364
PET+
n=89
n=31
EBUS+
n=22
EBUS- 
n=9
PET-  
n=275
n=1
EBUS+
n=0
EBUS- 
n=1
Fig. 3. Overview of the number of analyzed LN PET and EBUS-NA in 28 patients from Maastricht. * 5 LN samples were not representative at pathological examination.
Abbreviations: LN = lymph node; PET+: with pathological FDG-uptake; PET: no pathological FDG-uptake; n = number of LN.
4 Node irradiation in NSCLC: added value of E(B)US-NAFDG-PET–CT staged locally advanced NSCLC (Fig. 1). This overview
can also be used as a guide during multidisciplinary discussions to
decide whether further diagnostic procedure for nodal evaluation
is necessary. We further give some general recommendations on
the use of E(B)US-NA and nodal irradiation that can be used by
the radiation oncologist in daily clinical practice (Table 2). This
algorithm and these recommendations are of special interest when
using newer techniques such as IMRT or VMAT. When treating
NSCLC with 3D-CRT, only FDG-PET positive lymph nodes (LN) are
included in the gross tumor volume (GTV) [16], as it has previously
been shown that PET-based selective nodal irradiation is a safe
strategy [3,4]. An important contributive factor for the few
observed isolated nodal failures with 3D-CRT is the incidental irra-
diation of uninvolved mediastinal lymph node areas located in the
proximity of the GTV [7,8]. But, with newer techniques such as
IMRT or VMAT, the dose to non-involved adjacent LN decreases
[3,8], which raises the question whether FDG-PET–CT-based delin-Please cite this article in press as: Peeters ST et al. Selective mediastinal node irr
(B)US-NA information in addition to PET–CT for delineation?. Radiother Oncoleation is still safe [7]. Addition of E(B)US-NA to an integrated FDG-
PET–CT scan increases the accuracy of mediastinal LN-staging [19].
In clinical practice however, invasive staging is not always rou-
tinely done to help defining radiation volumes and all lymph node
stations are not readily accessible. We therefore evaluated the
impact of adding E(B)US-NA to FDG-PET–CT in the specific context
of selective nodal irradiation.
We calculated that addition of E(B)US-NA decreases the false
negative rate of a FDG-PET–CT scan, which drops with 10% for
enlarged LN (from 13% to 3%) and with 5% for normal-sized LN
(from 6% to 1%) (Fig. 1). For PET-positive but E(B)US-NA-negative
LN however, we calculated that the false negative rate of E(B)US-
NA is still 14%-16%, which we consider to be too high to be omitted
from the GTV, except if another valid benign reason for PET-
positivity is found at pathological examination. Only in this latter
situation the volume of the GTV will be smaller compared with
FDG-PET-based delineation only [16]. In all other situations theadiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E
(2016), http://dx.doi.org/10.1016/j.radonc.2016.05.023
Table 2
Summary of recommendations for nodal GTV delineation based on FDG-PET–CT and E(B)US-NA in daily clinical practice.
When incidental nodal irradiation is low, such as with IMRT or VMAT, it is advised to add E(B)US-NA to FDG-PET–CT for mediastinal staging as it may
 decrease geographical miss
 detect other benign reasons for PET-positivity
 confirm malignancy in PET-positive LN
Do NOT exclude LN that are PET-positive and E(B)US-negative from GTV as FN rate remains high (14%-16%), except if
 a clear benign reason for PET-positivity is found at pathological examination e.g. anthracosilicosis or granulomatosis
 high suspicion of infection with symmetrical pattern and less FDG-avid compared with primary tumor; take into account clinical parameters
 negative pathology at E(B)US-NA is confirmed by mediastinoscopy
Select carefully which LN station to be sampled with E(B)US under local anesthesia
 confirm malignancy or find benign etiology for PET-positivity
 sample ‘‘suspicious” PET-negative LN
 consider to discuss the selection of critical LN with endoscopist beforehand
 E(B)US should be performed after FDG-PET–CT scan to avoid FN PET-positive LN
Abbreviations: GTV = gross tumor volume; E(B)US-NA = endobronchial/esophageal ultrasound with needle aspiration; IMRT = intensity-modulated radiotherapy;
VMAT = volumetric arc therapy; FN = false negative.
S.T. Peeters et al. / Radiotherapy and Oncology xxx (2016) xxx–xxx 5GTV volume will be identical or increased. Pathology-confirmed LN
should obviously be included in the nodal GTV. Only LN that are
both PET negative and E(B)US-NA-negative can safely be omitted
from the GTV, independently from the size of the LN.
This algorithm was first tested on 40 patients from Leuven,
where the addition of E(B)US-NA to FDG-PET–CT resulted in avoid-
ance of a geographical miss in 2 patients (5%; 95% CI 0–12%). This
result was externally validated in 28 patients from Maastricht
where a geographical miss was avoided in 1 patient (4%; 95% CI
0–10%). However, the question remains whether this decrease of
4–5% is relevant, given the wide confidence intervals. On the one
hand, stage III NSCLC patients have dismal prognosis, and therefore
any gain in local control may seem relevant. On the other hand
most relapses occur as distant metastases, often in combination
with a locoregional recurrence. In those situations nodal failures
are not relevant for survival. For these 3 patients with a geograph-
ical miss without E(B)US-NA, we calculated the decrease in dose to
this missed LN if it would have been excluded from the total PTV in
the IMRT plans (results not shown). The mean dose to PTV of this
LN decreased from 66 Gy to 41 Gy. Obviously no conclusions can
be drawn from these 3 patients concerning the effect on dose to
the LN.
Another reason for adding E(B)US-NA to PET–CT is that a benign
reason for PET-positivity, such as anthrocosilicosis may be found,
allowing to exclude LN from the GTV (Table 2). In the patient group
from Leuven, this was the case in 1 patient. In this patient the LN
was less FDG-avid compared with the primary tumor and
dust-laden macrophages were found. Therefore, caution is needed
when using this algorithm as it does not take into account other
factors such as the intensity of the nodal PET-positivity compared
to the primary tumor or the spatial pattern and/or number of
PET-positive LN. The co-existence of inflammatory lung disease
(COPD, granulomatous disorders, hypersensitivity pneumonitis,
pulmonary fibrosis, cryptogenic organizing pneumonia. . .) may
influence the clinical interpretation of the nodal PET-positivity.
For example, the radiation oncologist can decide to omit mediasti-
nal and hilar LN from the GTV in a patient with symmetrical PET-
positive LN in which pathology of the E(B)US-NA demonstrates a
granulomatous reaction in all sampled nodes. Or if inflammation
is suspected with normal LN at pathology, prescription of antibi-
otics followed by a repeat FDG-PET–CT scan may be considered.
As clinical interpretation of nodal PET-positivity is sometimes dif-
ficult, discussion of these patients at the multidisciplinary board
concerning this issue is strongly recommended.
The addition of a videomediastinoscopy when E(B)US-NA based
cytology is negative increases the negative predictive value from
85% to 93%, but a videomediastinoscopy has a significantly higher
morbidity than E(B)US-NA, which is routinely performed underPlease cite this article in press as: Peeters ST et al. Selective mediastinal node irr
(B)US-NA information in addition to PET–CT for delineation?. Radiother Oncollocal anesthesia with moderate sedation [19]. In order to avoid
additional morbidity we usually do not perform a videomedi-
astinoscopy when E(B)US-NA only shows normal lymphocytes in
PET-positive nodes, but include these LN within the GTV in daily
clinical practice. This will result in overtreatment in false positive
LN, but in most cases will probably not add substantial toxicity
from the radiotherapy.
One of the challenges with E(B)US-NA is the number of sampled
lymph nodes. In general, it is recommended to inspect at least 3
mediastinal LN stations (always station 7, ipsilateral station 4
and contralateral station 4), and to sample at least one LN per
station, especially suspicious LN and/or FDG-avid lymph nodes
[20–22]. In our study the number of E(B)US-NA samples per
patient may seem to be relatively low with a mean of 2.1 and 1.3
LN stations sampled per patient in Leuven and Maastricht,
respectively. But when an inspected LN station does not contain
a visible LN, sampling is impossible. But on the other hand this
low number may result in an underestimation of the geographical
misses. The lower number in Maastricht compared to Leuven may
be due to the policy that only LN that may affect the radiation vol-
ume were sampled. According to the proposed algorithm (Fig. 1),
FDG-PET-positive LN are included in the GTV anyway, except if E
(B)US-NA shows another reason for PET-positivity (e.g. anthra-
cosilicosis). We therefore suggest to sample with E(B)US-NA at
least a PET-positive LN to confirm malignancy, and in addition to
carefully search for, and sample PET-negative LN stations that
may influence nodal stage and GTV.
A possible limitation of the study is that the literature-based
expected prevalence of cancer shown in Fig. 1 was only partly
observed in the results shown in Fig. 2. Especially for enlarged
PET-negative LN a discrepancy was seen. Results of Fig. 1 are based
on data from large studies where LN positivity was usually
confirmed by mediastinoscopy or thoracotomy, whereas in Fig. 2
data are retrospective (although based on prospectively gathered
databases), but reflecting routine clinical situations where the
number of pathology samples per patient is lower. We therefore
believe that the algorithm can be used for decision-making in daily
clinical practice.
Another limitation is that no data on locoregional recurrence
and overall survival were presented as the number of patients is
too small. The patient data set contained 40 patients in Leuven,
and 28 patients in the external dataset from Maastricht. In these
patients, a large number of LN were inspected: 13 LN stations on
FDG-PET–CT scan (=884 LN stations) and 7 LN stations with E(B)
US-NA (=476 LN stations). A total of 119 LN were sampled with E
(B)US-NA. We therefore consider the patient data sets large enough
to support the proposed concept, but not to analyze locoregional
recurrences or overall survival.adiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E
(2016), http://dx.doi.org/10.1016/j.radonc.2016.05.023
6 Node irradiation in NSCLC: added value of E(B)US-NAIn conclusion, the addition of E(B)US-NA to FDG-PET–CT for
mediastinal staging in locally advanced NSCLC decreases the risk
of a geographical miss with 4–5%. Whether addition of E(B)US-
NA will impact on survival is however unknown as isolated nodal
failures are rare. On the other hand, in daily clinical practice it is
sometimes difficult to decide whether a LN should be included in
the GTV in case of conflicting results on PET and E(B)US-NA. The
algorithm and recommendations are therefore proposed to guide
the radiation-oncologist in the delineation of the nodal GTV
(Fig. 1, Table 2). LN that are both PET-positive and E(B)US-NA-
negative should be included in the GTV as FN-rates remain high,
except if a valid benign reason for PET-positivity is found at patho-
logical examination.
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